Redhill Biopharm Stock Price, News & Analysis

RedHill Biopharma (NASDAQ: RDHL) presented a comprehensive business update at the Sachs' European Life Sciences CEO Forum, highlighting significant developments. The company announced an out-licensing deal with Hyloris for RHB-102, potentially worth $60 million plus royalties. Additionally, they initiated a Bayer-funded Phase 2 study of opaganib with darolutamide for advanced prostate cancer.

Notable progress with Talicia® includes: surpassing 100,000 prescriptions while maintaining its position as the #1 brand prescribed by gastroenterologists; Humana® Part D Plan coverage expansion adding 8+ million Medicare lives; inclusion as a first-line treatment option in ACG Clinical Guidelines; and FDA approval for more convenient three-times daily dosing. The company is also exploring new markets, with recent launch in UAE and ongoing evaluations for additional marketing authorizations.

RedHill Biopharma has licensed RHB-102 (Bekinda®) to Hyloris Pharmaceuticals for commercialization worldwide excluding North America. The deal includes an upfront payment and up to $60 million in potential milestone payments, plus up to mid-20s percent royalties on revenues.

RHB-102 is a once-daily, extended-release oral tablet formulation of ondansetron in development for multiple indications. The UK MHRA has provided a clear pathway for a Marketing Authorization Application, potentially making it the first oral 24-hour extended-release ondansetron for treating chemotherapy/radiotherapy-induced nausea and vomiting.

RedHill will continue development for FDA approval in the U.S., while Hyloris handles development, regulatory and commercialization activities in its territories. The global antiemetics market was valued at approximately $7.5 billion in 2023 with expected growth at 6% CAGR through 2030.

RedHill Biopharma has initiated a Phase 2 clinical study evaluating opaganib combined with Bayer's darolutamide for metastatic castrate-resistant prostate cancer (mCRPC). The 80-patient placebo-controlled study, financially supported by Bayer and Ramsay Hospital Research Foundation, will be led by Professor Lisa Horvath from Chris O'Brien Lifehouse and ANZUP.

The study will use a companion lipid biomarker test (PCPro) to select mCRPC patients with poor prognosis from standard treatment. The primary endpoint is improved 12-month radiographic progression-free survival. The research aims to overcome resistance to standard androgen receptor pathway inhibition treatment.

Prostate cancer, the second most diagnosed cancer globally with 1.5 million new cases annually and 400,000 deaths, represents a $12 billion market. The study's approach of developing therapeutic combinations with the PCPro biomarker is unique in metabolic targeting for metastatic prostate cancer.

RedHill Biopharma (Nasdaq: RDHL) announced two significant developments for its H. pylori treatment Talicia®. First, Humana's Part D Plan now covers Talicia, providing access to over 8 million additional Medicare beneficiaries without requiring prior therapeutic steps or authorization, effective January 1, 2025.

Additionally, new data published in The Journal of Clinical Pharmacology supports Talicia's FDA-approved label change to a more convenient three-times daily (TID) dosing schedule with meals. The study demonstrated pharmacokinetic equivalence between the new TID regimen and the previous every 8-hour (Q8H) dosing schedule.

Talicia continues to be the most prescribed branded H. pylori therapy by U.S. gastroenterologists and is listed as a first-line treatment option in the updated American College of Gastroenterology Clinical Guideline.

RedHill Biopharma (Nasdaq: RDHL) announced positive results from new in vivo studies of opaganib for treating gastrointestinal acute radiation syndrome (GI-ARS). The studies were conducted under the U.S. government's Radiation and Nuclear Countermeasures Program (RNCP) contract and confirmed opaganib's protective activity.

The company is in discussions with the National Institute of Allergy and Infectious Diseases (NIAID) regarding the next development phase following the FDA's Animal Rule pathway. Opaganib, an oral small molecule with a five-year shelf-life, is being developed as a potential medical countermeasure for GI-ARS, for which there are currently no approved therapies.

RedHill Biopharma has been awarded approximately $8 million plus costs in a summary judgment by the New York Supreme Court in its legal proceedings against Kukbo Co. The amount consists of $6.5 million plus interest of approximately $1.5 million. The case involves Kukbo's failure to make agreed payments to RedHill under a Subscription Agreement from October 25, 2021, and an Exclusive License Agreement from March 14, 2022. The Court dismissed all of Kukbo's counterclaims. Kukbo retains the right to seek an appeal of the judgment.

RedHill Biopharma (Nasdaq: RDHL) has been selected to present its drug opaganib at the JPEO-CBRND's 'Host Directed Therapeutics Industry Day' on October 29-30, 2024, in Alexandria, VA. The selection was based on the drug's demonstrated capabilities in prophylaxis and treatment of exposure to viruses, bacteria, and toxins.

The JPEO-CBRND, which manages U.S. government investments in chemical, biological, radiological, and nuclear defense equipment and medical countermeasures, will host the presentation. Opaganib, a novel host-directed oral drug, is being developed for various applications including oncology, viral infections, inflammatory diseases, and chemical/nuclear protection, with multiple ongoing U.S. government collaborations.

RedHill Biopharma (Nasdaq: RDHL) has announced a collaboration with Duke University School of Medicine to develop opaganib as a potential countermeasure against phosgene inhalation injury. The research aims to advance opaganib into U.S. government-sponsored development under the FDA's Animal Rule pathway to approval.

Phosgene, a toxic chemical used in industrial processes, poses a significant risk to public safety. The EPA has identified 123 sites in the U.S. that could potentially expose millions to phosgene. Currently, there is no approved antidote for phosgene inhalation injury, which can cause severe respiratory damage.

Opaganib, RedHill's novel, host-directed drug, is being developed for various indications, including chemical and nuclear/radioprotection. The collaboration with Duke University aims to determine if opaganib can provide protection against phosgene-induced damage and potentially be stockpiled for emergency use.

RedHill Biopharma has secured U.S. government funding through BARDA to advance opaganib for Ebola treatment. The funding will support the development of opaganib as a medical countermeasure (MCM) for Ebola virus disease (EBOV). Recent U.S. Army-funded studies showed that opaganib significantly increased survival in an EBOV model. Opaganib is a novel, potentially broad-acting drug with mutation-resistant antiviral and anti-inflammatory activity.

The development comes as there is an urgent need for effective and usable therapies for EBOV, which has a fatality rate of around 50% according to WHO. Opaganib represents an alternative host-directed therapeutic strategy for biodefense and global health preparedness. The drug is also being developed for other indications, including COVID-19, ARDS, and radiological and chemical protection.